Enpatoran Targets Skin and Systemic Symptoms
Merck has dosed the first patient in its Phase 3 study of enpatoran, a new oral treatment for lupus patients with active skin manifestations. The trial, part of the global ELOWEN program, aims to evaluate the effectiveness of enpatoran in addressing both skin and systemic symptoms of lupus.
Lupus is a chronic autoimmune disease affecting various organs, including the skin, joints, kidneys, and central nervous system. Up to 85% of patients experience skin issues. These manifestations are not only visible but also indicative of underlying inflammation, making disease control challenging with existing treatments.
David Weinreich, Global Head of R&D and Chief Medical Officer at Merck, stated, “People living with lupus continue to face significant challenges in achieving disease control and are very often affected by itchy, painful and stigmatized skin manifestations.” Enpatoran is designed to target these symptoms by inhibiting specific immune pathways.
Phase 3 Study Details
The ELOWEN-1 and ELOWEN-2 studies are being conducted at 266 sites across 26 countries. Each study will enroll approximately 200 participants, with the primary endpoint being a change in the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI-A).
Professor Eric Morand, principal investigator, noted, “The ELOWEN programme builds on Phase 2 findings, where enpatoran demonstrated clinically meaningful improvements in patients with active cutaneous manifestations, regardless of their underlying lupus diagnosis.”
The studies are double-blind, placebo-controlled trials where enpatoran is administered twice daily in addition to the standard of care. Results from these trials are expected to provide crucial insights into the treatment’s potential to broaden therapeutic options for lupus patients.
Enpatoran targets toll-like receptors 7 and 8, which play a role in lupus-related inflammation. By modulating these pathways, enpatoran may address a key aspect of lupus that remains difficult to manage with current treatments while preserving broader immune function.
Skin manifestations of lupus can present as inflamed, photosensitive lesions on the face, scalp, and other areas. These lesions may lead to scarring or pigment changes and can be life-altering. Despite their prevalence, many patients do not achieve adequate disease control.
The ELOWEN programme is designed to explore potential links between skin and systemic disease activity. It aims to redefine the approach to lupus treatment by understanding both visible skin manifestations and systemic activity.
Enpatoran, an oral TLR7/8 inhibitor, is designed for lupus patients with active cutaneous manifestations. The goal is to broaden the treatment paradigm beyond the current standards. The ELOWEN programme evaluates enpatoran’s impact on both skin and systemic symptoms in lupus patients. This research could reveal new connections between skin and systemic disease activity.
